GCG and Alzheimer disease: Hence, untoward actions on either anxiety or motor activity cannot be considered confounds when evaluating liraglutide and twincretin mitigation of mTBI-induced cognitive impairments, and these positive actions are in line with prior reports regarding the cognitive alleviation provided by incretin analogs following an mTBI challenge (Rachmany et al., 2013; Li et al., 2015; Tamargo et al., 2017; Bader et al., 2019; Glotfelty et al., 2019), as well as in Alzheimer’s disease models (Faivre and Holscher, 2013; Shi et al., 2017; Batista et al., 2018; Glotfelty et al., 2019).